• About
  • Meet The Team
  • Privacy Policy
Saturday, January 16, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Why Plus Therapeutics Inc [NASDAQ: PSTV] Is a Good Buy at Current Prices

Company just got fast track designation for new Glioblastoma treatment

by Nicholas K
September 16, 2020
in Featured, Investing
Share on FacebookShare on Twitter

Plus Therapeutics Inc [NASDAQ: PSTV] has been trading in a bullish channel for months now. Yesterday, the stock gained some more upside momentum and closed the day with gains of 24%. Yesterday’s rally followed the company’s announcement that it had got fast track designation from the U.S FDA for its new Glioblastoma treatment.

With the fast track designation, the company will now have access to a number of benefits. For starters, it will be in a position to hold more regular meetings with the FDA on issues touching on its drug development process.

The company will also have regular communication from the FDA on many issues including the design of its upcoming clinical trials and the biomarkers that it will use in its process. On top of that, the company will be eligible for accelerated review and approval whenever it meets the laid down criteria.

Most importantly, the company will be in a position to submit sections of its new drug application whenever they are completed rather than waiting for the entire application to be reviewed by the FDA. This puts the company in an advantageous position in its quest to develop and sell its new treatment for Glioblastoma.

Commenting on the  fast track designation, the company CEO,  Dr,  Marc Hedrick stated that the award of a fast track designation was a validation of the company’s treatment’s potential for people suffering from recurring cases of glioblastoma, and do not have any viable treatment options at the moment. He added that now that the company had received the fast track designation, it planned on moving the trial to cohort, a major step toward making the new therapy a reality.

From an investor perspective, the FDA fast track designation means that the company is close to unlocking a new revenue stream. This would have the effect of driving up the company’s value and the stock price. For this reason, buyers are likely to keep bidding up this stock in the near-term.

The stock is also likely to be the uplifted by the increased optimism in the market. Stocks are on the rise on hopes of a potential COVID-19 vaccine in the near-term. In this environment, any stock that has good fundamentals stands to gain at a higher rate than the rest of the market.

About Plus Therapeutics Inc

Plus Therapeutics Inc is a pharmaceutical company that develops treatments for cancer and other ailments. It is based in Austin, Texas.

 

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: FeaturedNASDAQ: PSTVPlus TherapeuticsPlus Therapeutics StockPSTVPSTV Stock

Related Posts

Top 15 Information Technology Stocks You Should Be Holding
Featured

Why Momo Inc (MOMO) Is Attracting Investors?

January 14, 2021
Telecom Stocks to Look Out for in 2021
Featured

Telecom Stocks to Look Out for in 2021

January 13, 2021
TG Therapeutics (NASDAQ: TGTX) Ublituximab Receives Fast Track Designation In US
Featured

Why T2 Biosystems Inc. (TTOO) is stock surging in the Pre-market hours today?

January 12, 2021
Top 20 Banking Industry Stocks For October 2020
Featured

Are These The Best Battery Stocks To Buy This Year

January 11, 2021
Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
Featured

Can We Expect Growth From General Electric (GE) In 2021?

January 11, 2021
Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
Featured

Where The Li Auto (LI), XPeng (XPEV) Stocks Are Heading To

January 8, 2021
Next Post
Stocks to Watch as Positive Sentiment Takes Hold in the Equity Markets

Should You Be Holding FedEx (NYSE: FDX) Right Now?

Early Morning Vibes: The 4 Best Stocks To Buy Now

Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
by Shan Zee
January 14, 2021
0

American stock markets ended trading largely in the green zone on January 13. The S&P 500 index improved to 3810...

Read more

Early Morning Vibes: Check Out These 4 hot Stocks Right Now

GILT Stock
by Shan Zee
January 12, 2021
0

On January 11, American stock markets closed in the red. The S & P500 index fell 0.66% to 3800 points,...

Read more

Early Morning Vibes: Watch These 4 Stocks Today

Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
by Shan Zee
January 13, 2021
0

The US stock indexes were traded in small ranges on January 12. The S&P 500 has risen symbolically by 0.04%...

Read more

Early Morning Vibes: 4 Stocks We Like for Friday

by Shan Zee
January 15, 2021
0

On January 14, the American stock indices closed in the red. The S&P 500 index dropped 0.38% to 3796 points,...

Read more

Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Shan Zee
January 11, 2021
0

Last week indices in the United States managed to set fresh records on the price boards. Interestingly, we saw Wall...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.